Article

Melinda Liggett Irwin on Exercise and Fatigue in Women Diagnosed With Ovarian Cancer

Author(s):

Melinda Liggett Irwin

Melinda Liggett Irwin, discusses The Women's Activity and Lifestyle Study in Connecticut (WALC) study, a randomized trial of exercise on quality of life and fatigue in women diagnosed with ovarian cancer.

Melinda Liggett Irwin, Associate Professor of Epidemiology (Chronic Diseases), Yale School of Public Health, discusses The Women’s Activity and Lifestyle Study in Connecticut (WALC) study, a randomized trial of exercise on quality of life and fatigue in women diagnosed with ovarian cancer.

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Dr. Valerie Lee discussed emerging targeted therapies and personalized medicine approaches that are showing promise for those with gastrointestinal cancer.
Image of doctor.
Although late-stage kidney cancer generated poor survival rates for over two decades, significant progress is being made in the treatment of the disease.
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Related Content
image of dr. Lillian Siu.
April 3rd 2025

Breaking Down Early Signs and Symptoms of Head and Neck Cancer

Dr Lillian Siu
April is Head and Neck Cancer Awareness Month, and it is important to be aware of early signs and symptoms of the disease, as well as when to seek care.
cancer horizons logo: a white microphone on a navy blue background
March 11th 2024

Oncology Approvals, Psychological Outcomes for Survivors and an Ovarian Cancer Vaccine

Alex Biese Brielle Benyon
Last week we saw some FDA approvals come through, as well as research that explored the psychosocial outcomes of individuals who survived pediatric rhabdosarcoma.
Ovaries.
March 31st 2025

Relacorilant Plus Chemo Meets Primary Goal in Ovarian Cancer Trial

Spencer Feldman
The phase 3 trial showed relacorilant with chemotherapy improved progression-free and overall survival in platinum-resistant ovarian cancer.
Shannon Miller smiling at a podium while delivering the keynote address at the 2023 Extraordinary Healer event | Image credit: © ATA-GIRL PHOTOGRAPHY
May 4th 2023

Olympian Shares Her Cancer Experience: ‘Give Yourself Grace’

Brielle Benyon
Olympic gymnast, Shannon Miller, sat down with CURE® to discuss her experience with a rare type of ovarian cancer, and how her competitive mindset helped her through.
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized: © Tada Images - stock.adobe.com
March 24th 2025

Phase 3 Study Design Finalized with FDA for IMNN-001 in Ovarian Cancer

Alex Biese
The phase 3 trial design evaluating IMNN-001 in newly diagnosed advanced ovarian cancer has been finalized among regulatory agencies.
Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer: ©mi_viri - stock.adobe.com.
March 17th 2025

Elahere Shows Consistent Survival Benefit in Ovarian Cancer Subset

Spencer Feldman
Elahere shows consistent survival benefits in patients with folate receptor alpha-positive platinum-resistant ovarian cancer in the MIRASOL trial.